Codi QR

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients

Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing,...

Descripció completa

Guardat en:
Autors principals: Luigi Della Gravara, Ciro Battiloro, Antonietta Letizia, Rosa Cantile, Vito D'Agnano, Giacomo Sica, Danilo Rocco
Format: Artigo
Idioma:Inglês
Publicat: MDPI AG 2021-06-01
Col·lecció:Journal of Molecular Pathology
Matèries:
advanced NSCLC
immunotherapy
predictive biomarkers
PD-L1
TMB
TILS
Accés en línia:https://www.mdpi.com/2673-5261/2/2/17
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars